These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24840263)

  • 1. Lipid lowering in liver and chronic kidney disease.
    Herrick C; Litvin M; Goldberg AC
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):339-52. PubMed ID: 24840263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and the liver.
    Herrick C; Bahrainy S; Gill EA
    Cardiol Clin; 2015 May; 33(2):257-65. PubMed ID: 25939298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
    Athyros VG; Tziomalos K; Karagiannis A
    Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
    Zoungas S; Curtis AJ; McNeil JJ; Tonkin AM
    Clin Pharmacol Ther; 2014 Aug; 96(2):192-205. PubMed ID: 24727468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia in patients with chronic kidney disease.
    Hager MR; Narla AD; Tannock LR
    Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease].
    Monhart V
    Vnitr Lek; 2009; 55(7-8):671-8. PubMed ID: 19731874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
    Gonzalez L; Helkin A; Gahtan V
    Vasc Endovascular Surg; 2016 Feb; 50(2):119-35. PubMed ID: 26983668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG
    Curr Med Res Opin; 2014 Jan; 30(1):1-10. PubMed ID: 24063624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
    Pirro M; Del Giorno R; Lupattelli G; Mannarino MR; Roscini AR; Covelli D; Schillaci G; Pasqualini L; Bagaglia F; Siepi D; Mannarino E
    Eur J Intern Med; 2011 Aug; 22(4):412-7. PubMed ID: 21767761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations.
    Heine GH; Eller K; Stadler JT; Rogacev KS; Marsche G
    Pharmacol Ther; 2020 Mar; 207():107459. PubMed ID: 31863818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and the Liver.
    Herrick C; Bahrainy S; Gill EA
    Endocrinol Metab Clin North Am; 2016 Mar; 45(1):117-28. PubMed ID: 26893001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.